Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer

Jalfon, Michael J; Sakhalkar, Om; Lokeshwar, Soum D.; Marks, Victoria; Choksi, Ankur; Klaassen, Zachary; Leapman, Michael; Kim, Isaac Y.

doi:10.1007/s11934-023-01173-6

Curr Urol Rep

2023

DOI: 10.1007/s11934-023-01173-6

|View full text |Cite

Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer

Michael J Jalfon

Om Sakhalkar

Soum D. Lokeshwar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials

Fang,

MacDonald,

Gregg

et al. 2024

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Oligometastatic prostate cancer (OMPCa) is an intermediary state between localized and disseminated metastatic disease that has historically been treated with androgen deprivation therapy (ADT) and more recently with additional systemic therapies in combinations. However, cytoreductive control of the primary tumor may offer an opportunity to control the disease and enhance the response from systemic treatment. In this review, the use of local therapy to the prostate including cytoreductive prostatectomy (CRP), whole pelvis radiotherapy (RT), and focal therapies will be evaluated in the treatment of patients with newly diagnosed OMPCa. Recent findings Retrospective studies have demonstrated that some patients with OMPCa may indeed benefit from CRP. With preliminary trials demonstrating that CRP is safe and feasible, there are several phase II and III trials that are currently underway to investigate the role of CRP among patients with OMPCa. Results from several clinical trials have demonstrated that RT and ADT may benefit patients with OMPCa. Lastly, the evidence for focal and cryotherapy remains limited and further clinical trials are required. Summary OMPCa is a unique disease state that may benefit from local therapy to the primary tumor. Further study is required to guide treatment selection and patient candidacy. Several trials specifically are awaited to better define the treatment options for patients.

show abstract

Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials

Fang,

MacDonald,

Gregg

et al. 2024

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer

Cited by 1 publication

References 50 publications

Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials

Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials

Contact Info

Product

Resources

About